Summary
The pharmacokinetics of bacmecillinam and pivmecillinam were studied in healthy fasting volunteers given tablets in a cross-over, randomized order. The mean (±SD) peak levels of plasma mecillinam were 1.43±0.34, 2.73±0.43, and 4.62±1.41 mg/l after bacmecillinam 100, 200, and 400 mg and 2.38±0.65 mg/l after pivmecillinam 400 mg. The corresponding areas under plasma Vs time curves (AUC) were 2.21±0.19, 3.99±0.63, and 7.74±1.38 mg·h·l−1 for bacmecillinam and 5.35±0.93 mg·h·l−1 for pivmecillinam. The elimination half-lives were 0.8–1.1h for bacmecillinam and 0.7h for pivmecillinam. The 12 h urinary recovery of unchanged mecillinam after the 400 mg doses was 41% for bacmecillinam and 30% for pivmecillinam. The 400 mg dose of bacmecillinam gave a significantly higher plasma peak (p<0.001), AUC (p<0.001) and urinary recovery (p<0.001) than did pivmecillinam 400 mg. The plasma peaks appeared earlier and the rate of absorption was higher after bacmecillinam than after pivmecillinam (p<0.05). In conclusion, bacmecillinam had a better bioavailability than pivmecillinam in the tablet formulations studied. The AUC increased linearly with increasing doses of bacmecillinam.
Similar content being viewed by others
References
Neu HC (1976) Mecillinam, a novel penicillanic acid derivative with unusual activity against gram-negative bacteria. Antimicrob Agents Chemother 9: 793–799
Tybring L (1975) Mecillinam (FL 1060), a 6β-amidinopenicillanic acid derivative: in vitro evaluation. Antimicrob Agents Chemother 8, 266–270
Roholt K (1977) Pharmacokinetic studies with mecillinam and pivmecillinam. J Antimicrob Chemother 3 [Suppl B]: 71–81
Westerlund D, Carlquist J, Theodorsen A (1979) Analysis of penicillins in biological material by reversed phase liquid chromatography and post-column derivatization. Acta Pharm Suec 16: 187–214
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Hamilton Press, Hamilton, IL, USA
Weber E (1972) Grundriß der biologischen Statistik; 7th edn. Gustav Fischer, Stuttgart
Baltzer B, Lund F, Rastrup-Andersen N (1979) Degradation of mecillinam in aqueous solution. J Pharm Sci 68: 1207–1215
Lernestedt JO, Pring BG, Westerlund D (1980) Comparative clinical pharmacology of bacmecillinam alone or in combination with bacampicillin and of pivmecillinam. Curr Chemother Infect Disease, Am Soc Microbiol, Washington pp 314–316
Roholt K, Nielsen B, Kristensen E (1975) Pharmacokinetic studies with mecillinam and pivmecillinam. Chemotherapy 21: 146–166
Parsons RL, Hossack GA, Paddock CM (1977) Pharmacokinetics of pivmecillinam. Br J Clin Pharmacol 4: 267–273
Mitchard M, Andrew J, Kendall MJ, Wise R (1977) Mecillinam serum levels following intravenous injection: a comparison with pivmecillinam. J Antimicrob Chemother 3 [Suppl B]: 83–88
Andrews J, Kendall MJ, Mitchard M (1976) Factors influencing the absorption and disposition of mecillinam and pivmecillinam in man. Br J Clin Pharmacol 3: 627–632
Williams JD, Andrews J, Mitchard M, Kendall MJ (1976) Bacteriology and pharmacokinetics of a new amidinopenicillin mecillinam. J Antimicrob Chemother 2: 61–69
Sjövall J, Magni L, Bergan T (1978) Pharmacokinetics of bacampicillin, pivampicillin, and amoxycillin. Antimicrob Agents Chemother 13: 90–96
Gambertoglio JG, Barriere SL, Lin ET, Conte JE (1980) Pharmacokinetics of mecillinam in healthy volunteers. Antimicrob Agents Chemother 18: 952–956
Bergan T, Engeset A, Olszewski W, Solberg R (1979) Pharmacokinetics of bacampicillin and bacmecillinam in plasma and peripheral lymph. Lymphology 12: 85–94
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Josefsson, K., Bergan, T., Magni, L. et al. Pharmacokinetics of bacmecillinam and pivmecillinam in volunteers. Eur J Clin Pharmacol 23, 249–252 (1982). https://doi.org/10.1007/BF00547563
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00547563